1st Order Pharma is a virtual, development-stage pharma company focused on advancing 1OP-2198, an IND-ready small molecule potassium channel opener, for unmet medical and orphan indications in neurology & neuro-ophthalmology.
1st Order Pharmaceuticals, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/1st-order-pharmaceuticals-inc.” connections=”true” suffix=””]
1OP seeks to advance its lead compound (1OP-2198) in multiple indications while minimizing drug development risk through intelligent drug development strategies based on the scientific principles of pharmacokinetics and pharmacodynamics (PK/PD).
In April 2017, Xenon Pharmaceuticals acquired a potassium channel modulator XEN1101 (formerly 1OP2198) for the potential treatment of epilepsy from 1st Order Pharmaceuticals on milestone payments of $48.7 million in 2017 including sales-based, sales royalties and other milestones.